SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novoste (novt)
NOVT 130.94+1.7%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dr.john who wrote (67)7/25/1999 10:08:00 AM
From: Oak Tree  Read Replies (1) of 100
 
Dr.john. I wouldn't think that directionality would help (the radiation target is probably the entire circumferential advantitial tissues. I'm also wonder how much additional cost (and cathlab tie) people are going to be willing to tolerate for an intravascular irradiation procedure (especially with capitation controlling costs). IVUS plus a directional radiation source is likely to be too expensive. Also, NOVT has the significant disadvantage of requiring a rather large tri-lumen catheter. This is already a problem in many prcedures -- I can't see the ESON device beating NOVT. Finally, they are no where near a far through the testing process.

The biggest threats to NOVT are the gamma 192Ir, and the dream of developing a gene therapy that will prevent restenosis. The latter is very unlikely to ever work -- but is a seductive idea that will generate the creation of many companies.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News